A practical reference on PPARδ: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-21 and is reviewed periodically as new material appears.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Schizophrenia Schizoaffective disorder most commonly in conjunction with either an antidepressant (in the case of the depressive subtype) or a mood stabilizer (in the case of the bipolar subtype). Antipsychotics possess mood stabilizing properties and thus they may be used as standalone medication to treat mood dysregulation. Acute mania and mixed episodes in bipolar disorder may be treated with either typical or atypical antipsychotics, although atypical antipsychotics are usually preferred because they tend to have more favourable adverse effect profiles and, according to a recent meta-analysis, they tend to have a lower liability for causing conversion from mania to depression. Psychotic depression. In this indication it is a common practice for the psychiatrist to prescribe a combination of an atypical antipsychotic and an antidepressant as this practice is best supported by the evidence. Treatment-resistant depression as an adjunct to standard antidepressant therapy. Given the limited options available to treat the behavioral problems associated with dementia, other pharmacological and non-pharmacological interventions are usually attempted before using antipsychotics. A risk-to-benefit analysis is performed to weigh the risk of the adverse effects of antipsychotics versus: the potential benefit, the adverse effects of alternative interventions, and the risk of failing to intervene when a patient's behavior becomes unsafe. The same can be said for insomnia, in which they are not recommended as first-line therapy.
For x = 1 and y = 2 the empirical formula H2S2O7 for disulfuric (pyrosulfuric) acid is obtained. Pure disulfuric acid is a solid at room temperature, melting at 36 °C and rarely used either in the laboratory or industrial processes — although some research indicates that pure disulfuric acid has never been isolated yet.
By looking at Relaxation dispersion plots the data collect information on the thermodynamics and kinetics between the excited and ground. Saturation Transfer measures changes in signal from the ground state as excited states become perturbed. It uses weak radio frequency irradiation to saturate the excited state of a particular nuclei which transfers its saturation to the ground state. This signal is amplified by decreasing the magnetization (and the signal) of the ground state. The main limitations in NMR is that its resolution decreases with proteins that are larger than 25 kDa and is not as detailed as X-ray crystallography. Additionally, protein NMR analysis is quite difficult and can propose multiple solutions from the same NMR spectrum. In a study focused on the folding of an amyotrophic lateral sclerosis involved protein SOD1, excited intermediates were studied with relaxation dispersion and Saturation transfer. SOD1 had been previously tied to many disease causing mutants which were assumed to be involved in protein aggregation, however the mechanism was still unknown. By using Relaxation Dispersion and Saturation Transfer experiments many excited intermediate states were uncovered misfolding in the SOD1 mutants.
In the early 2000s, 7-Eleven and Dentsu introduced a corporate mascot named Open-Chan (Open 小將), an extraterrestrial dog who wears a rainbow-shaped crown from a fictional planet known as Planet Open to be a "cartoon spokesperson" for the store chain in Taiwan. Open-Chan quickly grew in popularity among Taiwanese children soon after its initial debut. After Open-Chan's subsequent rise to prominence in Taiwan, the character was even introduced in Japan. The unique convenience store culture formed by President Chain Store (7-Eleven in Taiwan) has become a part of Taiwanese culture. 7-Eleven Taiwan also operates an MVNO called ibon mobile, which offers prepaid and postpaid SIM cards using the FarEasTone network.
Specimens may also be stored using nested protective packaging systems; one example is the "Swedish method", in which paper envelopes are placed in cardboard boxes and then in larger rigid boxes. The Muséum national d'histoire naturelle has described varied packaging approaches in its collections, including boxes, envelopes, bound herbarium boards, and specialised slide collections for microscopic groups. The general aim of curation is to preserve both the physical structure needed for morphological study and the chemical integrity required for molecular analysis. Drying techniques vary: heat drying at 40–50 °C (104–122 °F) typically favours the retention of microscopic structures, while freeze-drying preserves colour and macroscopic form at the cost of increased fragility. For damp or woody material, low-temperature drying with high ventilation helps prevent further fungal growth and may limit DNA damage. Although liquid preservation in alcohol or formalin maintains a specimen's three-dimensional shape, it often results in colour loss and DNA degradation. While liquid preservation in glass containers maintains a specimen's three-dimensional shape, the choice of preservation method involves trade-offs between physical integrity and the suitability of the material for future DNA analysis. Because many fungi change markedly in appearance during drying, collecting practice has long included recording features of the living fungus through notes and images; the research value of a specimen is increased when such derivative documentation remains linked to the specimen record.
Sources: en.wikipedia.org
During Bryson's 20-month tenure as Lilly's president and CEO, the company reported its first quarterly loss as a publicly traded company. In 1993, Randall L. Tobias, vice chairman of AT&T Corporation and a Lilly board member, was named Lilly's chairman, president, and CEO, the first president and CEO recruited from outside of the company. In 1994, Lilly separated its medical device division. It also acquired PCS Systems, the largest drug benefits health maintenance organization at the time, for $4 billion. Released in 1996, Zyprexa (Olanzapine) (for schizophrenia and bipolar disorder, as well as off-label uses) (see Illegal marketing of Zyprexa) was the company's best-selling drug through 2010, when the patent expired. In May 1996, the Food and Drug Administration approved gemcitabine (Gemzar) for the treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiation therapy. Gemzar is also routinely used to treat non-small cell lung cancer. In 1998, the company dedicated new laboratories for clinical research at the Indiana University Medical Center in Indianapolis. Sidney Taurel, former chief operating officer of Lilly, was named CEO in July 1998 to replace Tobias, who retired. Taurel became chairman of the board in January 1999. Taurel retired as CEO in March 2008, but remained as chairman of the board until 31 December 2008. John C. Lechleiter was elected as Lilly's CEO and president, effective 1 April 2008.
=== Preregistration === Coacillium (LH-8) – topical, other routes – alopecia areata, alopecia – various mechanisms of action Gecaxitinib (gecacitinib, jaktinib) – oral – alopecia areata – ACVR1 protein inhibitor, Janus kinase 1 inhibitor, Janus kinase 2 inhibitor, Janus kinase 3 inhibitor, TYK2 kinase inhibitor Ivarmacitinib (ARQ-252, ARQ-255, SHR-0302) – oral – alopecia areata – Janus kinase 1 inhibitor
Where Cs is the saturation solubility of the nanocrystal, C𝛼 is the solubility of the drug at a non-nano scale, σ is the interfacial tension of the substance, V is the molar volume of the particle, R is the gas constant, T is the absolute temperature, 𝜌 is the density of the solid, and r is the radius. The advantage of nanocrystals is that they can improve oral adsorption, bioavailability, action onset and reduces intersubject variability. Consequently, nanocrystals are now being produced and are on the market for a variety of purposes ranging from antidepressants to appetite stimulants. Nanocrystals can be produced using two different ways: the top-down method or the bottom-up method. Bottom-up technologies are also known as nanoprecipitation. This technique involves dissolving a drug in a suitable solvent and then precipitating it with a non-solvent. On the other hand, top-down technologies use force to reduce the size of a particle to nanometers, usually done by milling a drug. Top-down methods are preferred when working with poorly soluble drugs.
anthracis, as well. These enterotoxins are all produced in the small intestine of the host, thus thwarting digestion by host endogenous enzymes. The Hbl and Nhe toxins are pore-forming toxins closely related to ClyA of E. coli. The proteins exhibit a conformation known as a "beta-barrel" that can insert into cellular membranes due to a hydrophobic exterior, thus creating pores with hydrophilic interiors. The effect is loss of cellular membrane potential and eventually cell death. Previously, it was thought that the timing of the toxin production was responsible for the two different courses of disease, but it has since been found that the emetic syndrome is caused by the toxin cereulide, which is found only in emetic strains and is not part of the "standard toolbox" of B. cereus. Cereulide is a cyclic polypeptide containing three repeats of four amino acids: D-oxy-Leu—D-Ala—L-oxy-Val—L-Val (similar to valinomycin produced by Streptomyces griseus) produced by nonribosomal peptide synthesis. Cereulide is believed to bind to 5-hydroxytryptamine 3 (5-HT3) serotonin receptors, activating them and leading to increased afferent vagus nerve stimulation. It was shown independently by two research groups to be encoded on multiple plasmids: pCERE01 or pBCE4810. Plasmid pBCE4810 shares homology with the B. anthracis virulence plasmid pXO1, which encodes the anthrax toxin. Periodontal isolates of B. cereus also possess distinct pXO1-like plasmids. Like most of cyclic peptides containing nonproteogenic amino acids, cereulide is resistant to heat, proteolysis, and acid conditions. B.
The same month, she partnered with Models of Diversity to appear in a billboard campaign alongside a group of other women, raising awareness about the lack of diversity within fashion weeks. Collins said of the campaign that she was "Getting a bit sick of the fashion industry still not letting plus-size women walk the runways" adding that she felt "plus-size fashion was at an all time low" and that she was "shocked by how bad the regular sites had become". In November 2024, Collins attended the Swansea Christmas Parade as part of a collaboration with McDonald's for their "Gift Drop" campaign. For the event, she dressed in a red ball gown and offered the public the chance to try items from the companies' Festive Menu ahead of its launch, serving from a food van. In December 2024, after collaborating with Baileys Irish Cream and appearing at one of their events earlier in the year, she hosted The Baileys Christmas Sip and Sing event where she performed alongside The Gold Collective choir. Of the event, Collins said: "Tis the season to Baileys, honey! Christmas is all about bringing people together for a bit of festive joy, a Christmas singalong, and of course, some Baileys". In June 2025, Collins collaborated with the motorised kitchen appliances company Ninja to promote their slushy machine Ninja SLUSHi. In a social media video promoting the product, Collins was appointed the "GCEO" and expresses her distaste in the employees slushy ideas at a board meeting, before introducing her own that are based on her, named the "Gemma Tom Collins" and "Brentwood Bellini" respectively.
Sources: en.wikipedia.org
In the United States, alprazolam is a prescription drug and is assigned to Schedule IV of the Controlled Substances Act by the Drug Enforcement Administration (DEA). Under the UK drug misuse classification system, alprazolam is a Class C drug. In the UK, alprazolam is not available on the National Health Service (NHS) and can only be obtained on a private prescription. In Ireland, alprazolam is a Schedule 4 medicine. In Sweden, alprazolam is a prescription drug in List IV (Schedule 4) under the Narcotics Drugs Act (1968). In the Netherlands, alprazolam is a List 2 substance of the Opium Law and is available for prescription. In Germany, alprazolam can be prescribed normally in doses up to 1 mg. Higher doses are scheduled as Anlage III narcotic drugs and require a special prescription form. In Australia, alprazolam, as of February 2014, is a Schedule 8 medication. In the Philippines, alprazolam is legally classified as a "dangerous drug" under the Comprehensive Dangerous Drugs Act of 2002, along with other schedule drugs listed in the 1971 Convention on Psychotropic Substances. The importation of dangerous drugs including alprazolam, requires authorization from the Philippine Drug Enforcement Agency. Internationally, alprazolam is included under the United Nations Convention on Psychotropic Substances as Schedule IV.
== Society and culture == Terlipressin is available in United States, New Zealand, Australia, the European Union, India, Indonesia, Pakistan, UAE. It is sold under various brand names including Glypressin and Terlivaz.
Meanwhile, a Chilean squadron set sail on November 15, 1824, to help in the blockade of Callao, commanded by Vice Admiral Blanco Encalada, who had learned of the intentions of Bolívar and other Lima authorities to annex the southern archipelago due to their old ties. with Peru, when he landed with his fleet in Quilca on January 6, 1825, so in June he decided to return to Valparaíso with the Chilean fleet to report that the island should be conquered as soon as possible, even if that was to the detriment of the interests Peruvians.
Constipation refers to bowel movements that are infrequent or hard to pass. Constipation is a common cause of painful defecation. Severe constipation includes obstipation (failure to pass stools or gas) and fecal impaction, which can progress to bowel obstruction and become life-threatening.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.